INTRODUCTION
The intestinal epithelium displays a high renewal potential due in large part to the activity of intestinal stem cells (ISCs) (Clevers, 2013) . Targeting of the Lgr5 marker gene has recently led to the identification of a type of stem cell located in the mouse small intestine at the bottom of the crypt (Barker et al., 2007 (Barker et al., , 2009 . They give rise to the transit-amplifying (TA) crypt compartment, in which TA cells divide and migrate upward toward the crypt-villus junction (Clevers, 2013) . When committed TA cells reach this junction, they rapidly differentiate while continuing their upward migration (Clevers, 2013 ). This stem cell population has been shown to be very sensitive to transformation by adenomatous polyposis coli (APC) mutations that rapidly lead to adenoma formation (Barker et al., 2009 ). In contrast, TA cells, and more differentiated cells within the villus, although also capable of adenoma formation, will only do so after long latency periods (Schwitalla et al., 2013) . This suggests that stem cells are the most common origin of intestinal cancer (Barker et al., 2009 ). Furthermore, Lgr5-expressing cells have been detected within experimental adenomas, and their function has been shown by lineage-tracing assays. This supports the idea that normal tissue stem cells can contribute to cancer initiation and progression and is consistent with the cancer stem cell theory (Schepers et al., 2012) . If ISCs are the target of tumor-initiation factors, we can predict that increasing the number or proliferative activity of these cells will increase the risk of intestinal neoplasms as well as hamper their treatment. Therefore, a better understanding of the signaling cascades that regulate stem cell signaling is essential for the design of new and more efficacious therapies for intestinal tumors, as well as tissue regeneration after injury. We have addressed this fundamental biological problem in the context of protein kinase C z (PKCz) deficiency. PKCz and PKCl/i constitute the atypical protein kinase C (aPKC) family. Both aPKCs have been implicated in oncogenic transformation . A number of studies support the clinical relevance of PKCz as a tumor suppressor in several tissues, including the intestine (Galvez et al., 2009; Ma et al., 2013) . Thus, our own studies demonstrated that PKCz is downregulated in human colorectal cancers as compared to normal colon tissue and is underexpressed in cancers progressing to metastasis (Ma et al., 2013) . Interestingly, an inactivation mutation in PKCz (S514F) has been identified in human colon cancers (Galvez et al., 2009; Wood et al., 2007) . Our most recent studies demonstrated that PKCz deficiency promotes the plasticity necessary for intestinal cancer cells to reprogram their metabolism in order to survive in the absence of glucose and that the total-body loss of PKCz in mice results in enhanced intestinal tumorigenesis. Those results unveiled a critical role for PKCz as a tumor suppressor in cells metabolically stressed during tumor progression (Ma et al., 2013) . However, it remains to be determined whether PKCz is important in stem cell function related to tumorigenesis and under noncancer conditions, such as during tissue regeneration. Scale bars represent 100 mm. Results are presented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1 .
RESULTS

Loss of PKCz Results in Increased
Intestinal Stem Cell Activity As a first step in exploring the role of PKCz in ISCs, we used the Lgr5-EGFPires-CreERT2 knockin allele mouse strain crossed with Rosa26-LacZ reporter mice to generate Lgr5Cre-Rosa26-LacZ mice. In this mouse model, Lgr5 + cells were GFP labeled and the Lgr5Cre reporter was activated by injection of tamoxifen. This strategy allows for the purification of Lgr5 + cells by sorting using GFP as the marker, as well as the in vivo tracking of the subsequent fate of the progeny of these cells by X-gal staining of intestinal tissue (Barker et al., 2007 (Barker et al., , 2009 ). Of note, we found that PKCz was expressed both in the small intestine and in the colon and that its levels were specially enriched in ileum as compared to duodenum or jejunum ( Figure 1A ). To determine its expression in ISCs, we sorted GFP-positive epithelial cells from crypts isolated from ileum of Lgr5-EGFP-ires-CreERT2 mice. Fluorescence-activated cell sorting analysis distinguished an LGR5-GFP-high (GFP hi ) cell population, corresponding to the active stem cell pool, and an LGR5-GFP-low (GFP lo ) fraction that (legend continued on next page)
These two GFP-positive populations were sorted and separated from the LGR5-GFP-negative fraction (GFP ne ), after which mRNA was extracted from the different cell populations and analyzed by qRT-PCR to determine PKCz content. Interestingly, PKCz was expressed in the three cell fractions and highly enriched in the GFP lo cell population ( Figure 1C ). Consistent with these results, immunofluorescence staining of PKCz showed apical localization in epithelial cells in the crypt, including colocalization with crypt bottom stem cells with strong GFP expression ( Figure 1D ). The fact that PKCz was relatively enriched in the GFP lo population as compared to the GFP hi would suggest its potential stem cell-suppressor activity. Therefore, to determine whether PKCz deficiency in fact influences ISC activity, we carried out experiments in an organoid culture model system using intestinal crypts from wild-type (WT) or total-body PKCz knockout (PKCz KO) mice. This system assesses the activity of ISCs on the basis of their ability to drive the formation of organoids. Interestingly, PKCz deficiency led to increases in both the number and complexity (higher number of lobes) of intestinal organoids ( Figures 1E-1G ), strongly indicating that PKCz's role is to restrain the activity of ISCs. Consistent with this, gene transcripts of the stem cell markers Lgr5 and Bmi1 were upregulated in PKCz-deficient organoids as compared to WT controls (Figure 1H ). Similar increases in these markers were found in isolated intestinal epithelial cells (IECs) and in extracts from small intestine of PKCz KO mice ( Figures 1I and 1J) .
We next used the Lgr5Cre-Rosa26-LacZ knockin model described above, but bred into a PKCz KO background. In this system, injection of tamoxifen allows the stem cell progeny to be followed by X-gal staining. Notably, PKCz KO intestines had increased numbers of LacZ-stained cells, as compared with WT controls (Figures 1K-1M ). Staining appeared along the flanks of the crypt-villus units of PKCz-deficient intestines at day 5 after tamoxifen injection to a greater extent than in WT mice ( Figures 1K-1M ). This is in agreement with the idea that the loss of PKCz favors increased stem cell activity in the intestine. Interestingly, staining of these samples with markers of differentiated cell populations such as enterocytes (Figure S1A) , Goblet ( Figure S1B ), or Paneth ( Figure S1C ) cells did not show differences between the two mouse genotypes. Also, no major alterations were detected in polarity in PKCz KO intestines when several markers were analyzed by qRT-PCR or by immunohistochemistry of E-cadherin, Na/K-ATPase, or ZO-1 ( Figures S1D-S1F ), supporting the notion that the stem cell repressor activity of PKCz is not related to regulation of intestine epithelial cell polarity. Selective PKCz Deficiency in Lgr5 + Stem Cells Promotes Intestinal Tumorigenesis Dysregulation of stem cell activity by such as deletion of the tumor suppressor gene Apc has been associated with intestinal tumorigenesis in several systems (Barker et al., 2009 ). To determine whether the selective loss of PKCz in Lgr5 + ISCs enhances tumor-forming potential from these cells, we crossed Lgr5-PKCz WT/WT and Lgr5-PKCz fl/fl mice with APC fl/fl mice. These mice were subsequently injected with tamoxifen as described in Figure 3A , which generated Lgr5-PKCz (Barker et al., 2009) , the loss of APC in the Lgr5 population efficiently drove the induction of adenomas in the small intestine ( Figure 3B ). Interestingly, the number and size of these tumors were dramatically increased by the simultaneous deletion of APC and PKCz selectively in Lgr5 stem cells ( Figures 3B-3E ). In addition, the lack of PKCz in Lgr5 + cells enhanced tumor aggressiveness.
PKCz Deficiency Promotes Intestinal Regeneration
That is, whereas Lgr5-PKCz WT/WT /APC À/À mice only showed low-grade adenomas with hyperchromatism of nuclei, tumors generated from Lgr5-PKCz
high-grade adenomas, with nuclear atypia and marked architectural distortion, including some areas consistent with intramucosal adenocarcinoma, characterized by a cribriform pattern of growth and an expanding-type infiltration into the lamina propria ( Figure 3F ). In addition, a similar phenotype was found in the Results are presented as mean ± SEM. **p < 0.01, ***p < 0. 
Low PKCz Expression in Human Colon Adenocarcinoma Correlates with Stem Cell and YAP/b-Catenin Signatures
To assess the relevance of these findings to human disease, we performed gene set enrichment analysis (GSEA) of human colon adenocarcinoma samples using data obtained from The Cancer Genome Atlas Network (COAD data set) using the C2 Molecular Signatures Database (MSigDB, Broad Institute) to find gene expression signatures that correlated with PKCz expression. Notably, and consistent with our in vivo mouse model data, we found that human colon adenocarcinoma tumors with low levels of PKCz mRNA exhibited transcriptional profiles associated with an enrichment of stem cell signatures ( Figure 4A ). Also, PKCz mRNA levels negatively correlated in these human tumors with the stem cell marker genes Hopx and Bmi1 ( Figure 4B ). These results support the mouse studies demonstrating that PKCz restrains tumorigenesis by inhibiting ISC activity and are consistent with data showing that patients with low PKCz levels or high expression of stem cell genes have a significantly worse prognosis (Ma et al., 2013; Merlos-Suá rez et al., 2011) . To start addressing the potential signaling mechanisms regulated by PKCz in ISCs, we extended the GSEA analysis of the COAD data set using the C6 MSigDB that includes oncogenic signatures of signaling pathways deregulated in cancer. Of potential great relevance, this analysis revealed that low PKCz expression correlated with enrichment in Yap signaling (Figure 4C) . Furthermore, we found a significant inverse correlation between PKCz gene expression levels and those of Yap target genes such as CTGF and Cyr61 ( Figure 4D ). In addition, colon adenocarcinoma patients with low PKCz expression displayed significantly higher levels of Yap ( Figure 4D ). In line with these results, GSEA of a transcriptomic profiling of the human colorectal adenocarcinoma cell line SW480 with knockdown of PKCz (shPKCz) also identified ''Yap_up'' as significantly enriched in PKCz-deficient cells as compared to nontargeted control cells (shNT) ( Figure 4E ). This suggests that PKCz's mechanism of action could involve the repression of Yap signaling. Interestingly, Ingenuity Pathway Analysis of the same transcriptome revealed that the most significantly enriched genes in PKCz-deficient SW480 cells as compared to the PKCz-proficient controls fell in the canonical pathway category of ''Wnt/b-catenin signaling,'' with significant upregulation of b-catenin target genes (Figure 4F) . Importantly, PKCz levels displayed a significant inverse correlation with the b-catenin-dependent gene CD44 in human colon adenocarcinoma tumors ( Figure 4G ). In addition, these results are in good agreement with those obtained in a parallel effort using small interfering RNA (siRNA) screening to identify potential targets of PKCz in SW480 cells. Thus, when this screening was carried with a pooled siRNA library covering 252 components of major oncogenic pathways designed to identify genes that had a differential impact on the viability of PKCz-deficient SW480 as compared to shNT control cells, we found b-catenin as the top hit in the screen ( Figure 4H ; Table  S1 ). It should be noted that the Yap pathway was not included in the siRNA set used in this screening (Table S1 ). Collectively, the clinical data, together with the unbiased transcriptomic and functional genomic approaches, strongly suggest that Yap and b-catenin are potential targets of PKCz function.
PKCz Deficiency Results in Enhanced b-Catenin and Yap Signaling
To investigate whether PKCz represses ISC function through the regulation of b-catenin and Yap signaling, we first determined the expression of transcripts involved in these pathways upon deficiency of PKCz in the in vivo mouse models. Notably, we found that well established target genes of b-catenin and Yap, including Yap itself, were significantly upregulated in organoids ( Figure 5A ), IECs ( Figure 5B ), and small intestine extracts (Figure 5C ) from PKCz KO mice kept under basal conditions, as compared with WT controls. Furthermore, analysis of mRNA levels of Axin-2 and CTGF, targets of b-catenin and Yap, respectively, in the sorted GFP populations of Figure 1B , also revealed that both transcripts were reduced in the GFP lo population in which PKCz levels were enriched ( Figures 1B and 1C ). This is in keeping with the repression of these pathways by PKCz (Figure S2A ). In addition, PKCz-deficient intestines displayed increased nuclear Yap staining ( Figures 5D and 5E ). Likewise, staining of CD44, a downstream target of the Wnt/b-catenin pathway, was more intense and widespread in the mutant intestines ( Figure 5F ). Furthermore, immunoblot analysis showed increased b-catenin and Yap protein levels in IECs from PKCz KO mice ( Figure 5G ). Notably, Yap protein levels were also increased in IECs from Lgr5-PKCz À/À mice, as well as in organoid cultures from PKCz KO mice ( Figure 5H ). Similar results were obtained when IECs and tissues from IR-treated mice were analyzed for expression of Yap-or b-catenin-target genes ( Figures S2B-S2E ). Altogether, these results strongly suggest that PKCz is a direct or indirect negative regulator of b-catenin and Yap pathways, two important mediators in stem cell function.
Yap and b-Catenin Are Direct Substrates of PKCz
We next investigated the molecular mechanisms whereby PKCz specifically represses Yap and b-catenin. First, we found that PKCz interacted with Yap and b-catenin in cotransfection experiments ( Figures 6A and 6B) . Also, in vitro interaction assays using purified recombinant proteins demonstrate that the interaction of PKCz with Yap and b-catenin was direct (Figure 6C) . We also detected this interaction in immunoprecipitates of endogenous proteins ( Figure 6D ). More importantly, immunoprecipitation of endogenous PKCz pulled down not only Yap and b-catenin but also GSK3b and Axin1 ( Figure 6D ). These results suggest that PKCz is part of the b-catenin (legend continued on next page) destruction complex in which Axin1 acts as a scaffold protein orchestrating the phosphorylation and degradation of b-catenin . To more firmly establish this question, we treated HEK293T cells with Wnt3a and analyzed the potential recruitment of PKCz to the Axin complex. It is well established that cell activation by Wnt results in the degradation of Axin1, which correlates with b-catenin stabilization Mao et al., 2001; Tolwinski et al., 2003) . Interestingly, Axin1 was degraded and the coimmunoprecipitation with PKCz and GSK3b was reduced upon Wnt3a stimulation ( Figure 6E ). These results indicate that PKCz is a bona fide component of the Axin1 complex and therefore could be involved in the regulation of b-catenin stability and function. Given that Yap and b-catenin directly bind PKCz, a potential mechanism whereby PKCz impacts their function could be through direct phosphorylation. Therefore, we tested whether Yap and/or b-catenin could be phosphorylated by PKCz, using an in vitro phosphorylation assay with recombinant PKCz and purified bacterially expressed Yap and b-catenin. The results of this experiment demonstrated that in fact Yap and b-catenin are direct substrates of PKCz ( Figures 6F and 6G ). To map the phosphorylated sites in Yap and b-catenin, we used titanium dioxide (TiO 2 )-based phosphopetide enrichment on tryptic digests of in vitro phosphorylation reactions followed by high-performance liquid chromatography tandem mass spectrometry (MS/MS) analysis. Using this approach, we identified S109 and T110 as major PKCz phosphorylation sites in Yap and several sites of low abundance that included T119, S163, and S164 (Figure S3A) . To assess the relative contribution of sites S109 and T110, we performed an ATP analog-based in vitro phosphorylation assay with PKCz using recombinant WT-or S109A/T110A-Yap as substrates ( Figure 6H ). Consistent with MS/MS analysis, mutation to alanine of these two sites completely abolished Yap phosphorylation by PKCz. Interestingly, S109 and T110 sites were highly conserved among species ( Figure S3B ), which suggested an important role in Yap regulation.
Similar MS/MS analysis to map the sites phosphorylated in b-catenin by PKCz identified S45 and several sites of low abundance that included S552 and S675 ( Figure S3C ). S45, along with S33, S37, and T41 at the amino-terminal region of b-catenin, conforms to the consensus GSK3 phosphorylation sequence and, when phosphorylated, is critical for the recognition of b-catenin by the F box protein b-Trcp, which is an essential step for its ubiquitination and subsequent proteasome-mediated degradation (Clevers, 2013; Niehrs, 2012) . Importantly, phosphorylation of b-catenin's S45 precedes, and is required for, subsequent GSK3-mediated phosphorylation of S33, S37, and T41 and the ensuing degradation of b-catenin. Interestingly, in vitro phosphorylation assays followed by immunoblotting with a specific anti-phospho-S45-b-catenin antibody confirmed that S45 is a bona fide phosphorylation site of PKCz in b-catenin ( Figure 6I ). More importantly, immunoblotting of IEC extracts from Lgr5-PKCz À/À and WT mice, and organoid extracts from WT and PKCz KO mice demonstrated that the loss of PKCz resulted in a profound inhibition of b-catenin phosphorylation at S45, concomitant with the accumulation of total b-catenin levels (Figures 6J and 6K) . In contrast, analysis of IEC and organoid extracts revealed that in vivo PKCz deficiency did not inhibit b-catenin phosphorylation at S552 and S675 ( Figures 6J and 6K) , consistent with the finding that these sites were found in low abundance in the MS/MS proteomic analysis in vitro.
PKCz Regulates Protein Stability and Function of Yap and b-Catenin by Phosphorylation
To determine the functional relevance of Yap and b-catenin phosphorylation by PKCz, either WT or the nonphosphorylatable Yap S109A/T110A mutant was expressed along with increasing amounts PKCz, after which we assessed the effect of PKCz expression on the activity of Yap by using a TEAD-luciferase reporter. Notably, expression of either WT or mutant Yap was able to activate the TEAD-luciferase reporter to a similar extent ( Figure 7A ). However, the coexpression of PKCz resulted in inhibition of the TEAD-reporter activity induced by WT Yap, but not by mutant Yap ( Figure 7A ). This demonstrates that Yap function is directly regulated by phosphorylation in residues S109/T110. Of note, Yap function is restrained through phosphorylation by the Hippo kinases Mst1/2 and Lats (Barry and Camargo, 2013; Mo et al., 2014 ). Therefore, we tested whether Yap constructs containing mutations in the Mst or Lats phosphorylation sites, termed 2SA (S127/381A) and Yap5SA (S61/109/127/164/381), were also sensitive to PKCz's actions. Results of Figure S4A demonstrate that overexpression of PKCz was able to restrain TEAD-activity induced by Yap2SA with no effect on the activity of Yap5SA ( Figure S4A ). These data are consistent with the fact that the S109 phosphorylation site by PKCz is also mutated in the Yap5SA mutant, but not in the Yap2SA mutant, further reinforcing the notion that PKCz targets Yap at S109/T110 and in a manner that is likely independent of the Hippo/Mst cascade. Collectively, these results are consistent with our in vivo data shown above ( Figures 5A-5D ), demonstrating that PKCz deficiency resulted in increased Yap activity.
Interestingly, the levels of WT Yap, but not of the S109A/T110A mutant, were decreased by coexpression of PKCz ( Figure 7A ), demonstrating that this kinase regulates Yap transcriptional activity by controlling Yap levels through direct phosphorylation. 
(legend continued on next page)
This is consistent with our observations that Yap itself was upregulated in PKCz-deficient tissues in vivo (Figures 5D-5H ). In keeping with this conclusion, the S109A/T110A Yap mutant was significantly more stable than WT Yap in cycloheximidetreated cells (Figure 7B ), lending support to our hypothesis that PKCz represses Yap function by promoting its destabilization through direct phosphorylation of residues S109 and T110. Next, we determined the functional relevance of b-catenin phosphorylation at S45 by PKCz. Thus, we analyzed the effect of PKCz knockdown on b-catenin-induced transcriptional activity of a specific luciferase reporter construct termed TOPflash. In support of our hypothesis that PKCz is a negative regulator of the Wnt pathway, the ability of b-catenin to activate the TOPflash reporter was enhanced by PKCz knockdown ( Figure 7C ). In addition, expression of PKCz in cotransfection experiments resulted in the inhibition of TOPflash activity induced by WT b-catenin, but not by that of an S45A mutant, which correlated with decreased levels of WT b-catenin, but not the mutant protein, in the PKCzexpressing samples ( Figures 7D and 7E) . Collectively, these results establish PKCz as a negative regulator of b-catenin stability by phosphorylation of S45. Since this site has been shown to be a target of CKIa (Clevers et al., 2014; Niehrs, 2012) , we next determined whether its in vivo phosphorylation by PKCz is mediated by CKIa. Interestingly, PKCz-induced depletion of b-catenin levels in vivo was not affected by the knockdown of CKIa (Figure S4B) . These results establish that S45 is a direct target of PKCz in a CKIa-independent fashion.
Further supporting the functional relevance of PKCz regulation of b-catenin and Yap, we found that PKCz knockdown in SW480 colorectal carcinoma cells promotes the activation of the b-catenin and Yap reporters ( Figures 7F and 7G) . Notably, this correlated with increased levels of both transcriptional regulators in the PKCz-deficient cells ( Figure 7H ). Our previous studies in this system revealed the critical role of PKCz as a tumor suppressor in cancer cells undergoing nutrient stress (Ma et al., 2013) . Therefore, we hypothesized that PKCz is a signaling molecule in the repression of both b-catenin and Yap in response to nutrient deprivation. Interestingly, incubation of PKCz-proficient SW480 cells under nutrient stress conditions inhibited the nuclear localization of b-catenin and Yap ( Figure 7I ). Importantly, this effect was completely abrogated in PKCz-deficient SW480 cells ( Figure 7I) . Consistently, the levels of b-catenin and Yap downstream transcripts were higher in PKCz-deficient SW480 cells under stress conditions than in the shNT controls (Figure S4C) . Furthermore, knockdown of b-catenin or Yap inhibited the increased proliferation and survival of PKCz-deficient SW480 cells ( Figure S4D ). In order to establish the in vivo contribution of the b-catenin and Yap pathways to the mechanism of action of PKCz, we treated organoids from WT and PKCz KO mice with verteporfin, which inhibits Yap function by disrupting the Yap-TEAD interaction, or with a combination of DKK1 plus Iwr1, which are inhibitors of the Wnt cascade. Consistent with our hypothesis, the inhibition of both pathways rescued the phenotype of PKCz KO organoids (Figures 7J-7L ).
DISCUSSION
The identification of Lgr5 + cells as an ISC population has expanded our understanding of the intestinal regeneration processes induced in response to acute injury and opens up new avenues for research on the role and mechanisms of action of the stem cells in cancer initiation (Barker et al., 2009) . Since the intestinal epithelium has an inherently high cellular turnover, fueled by the activity of ISCs residing at the bottom of the crypts, it is difficult to envision how mutations could be passed along through successive generations if stem-cell-derived differentiated cells undergo apoptosis with a high frequency after terminal differentiation and are substituted by new epithelial cells. The existence of a pool of stem cells that could accumulate these mutations might account for the generation of tumors in the intestine and might offer possibilities for treatment as well as strategies for prevention of tumor initiation by blocking those pathways that are critical for the control of the stem-cell-driven carcinogenesis process (Anastas and Moon, 2013; Vermeulen and Snippert, 2014) . Understanding the biochemistry and signaling properties of these intestinal Lgr5 + stem cells will be instrumental in designing better strategies not only to prevent cancer but also to promote intestinal regeneration after acute or chronic damage, such as that triggered by chemoradiotherapies. Our recent results demonstrate that PKCz is a suppressor of tumor progression in intestinal carcinogenesis because it represses the ability of aggressive cancer cells to reprogram their metabolism under situations of nutrient stress in mouse and human cancers (Ma et al., 2013) . We show here that PKCz deficiency leads to greater levels of stem cell activity in vitro and in vivo, which triggers an enhanced regenerative response to acute intestinal insults. Loss of PKCz also results in greater tumorigenic activity of the stem cell population in the absence of the tumor suppressor APC.
Although several signaling pathways are involved in intestine homeostasis and regeneration, including, BMP, Shh, and Notch, Wnt signaling has attracted great attention due to the fact that it is the target of several cancer-driving mutations (Clevers et al., 2014) . Also, the Wnt/b-catenin cascade has been shown to be critical for the proliferation of ISCs and TA cells, as revealed by the lack of proliferative crypts in mice with deletion of its transcriptional partner Tcf4 (Korinek et al., 1998) . b-Catenin is the effector of the Wnt pathway and is associated with, and degraded by, the APC/Axin/GSK3b complex (Clevers et al., 2014; Niehrs, 2012) . Phosphorylation of b-catenin initially at S45 is a necessary event for GSK3b to sequentially phosphorylate residues S33, S37, and T41, creating a recognition motif for the E3-ligase b-Trcp that constitutively targets b-catenin for degradation (Clevers et al., 2014; Niehrs, (legend continued on next page) 2012). Upon stimulation of the pathway, these phosphorylation events and the subsequent degradation of b-catenin are impaired, and b-catenin thus accumulates in the nucleus and activates the transcription of several critical components of the proliferation and stem cell activity (Clevers et al., 2014; Niehrs, 2012) . Interestingly, we show here that PKCz's role as a suppressor of tumorigenesis and ISC activity is mediated by the direct phosphorylation of S45 in a CKIa-independent manner. Upon PKCz inactivation, which is common in human intestinal cancers and results in enhanced tumorigenesis in several mouse models (Ma et al., 2013) , b-catenin becomes more stable and accumulates in the nucleus of intestinal epithelial and stem cells. Along with Wnt/b-catenin, Yap has been proposed as an important regulator of ISC function (Clevers et al., 2014; Harvey et al., 2013; Mo et al., 2014) . Yap is directly phosphorylated by the kinases Lats1/2 that are under regulation of the tumor suppressor Hippo pathway that includes the kinases Mst1 and Mst2 and the adaptor Sav1 (Harvey et al., 2013; Mo et al., 2014) . Lats1/2-mediated phosphorylation of Yap S127 serves to promote its exclusion from the nucleus and its eventual degradation. Yap is expressed in both the small intestine and colon, displaying cytoplasmic localization in the upper regions of the crypt and villi whereas it is nuclear in the Lgr5 + ISCs (Barry and Camargo, 2013) . Even though the deletion of Yap has no significant effects on intestinal cell proliferation or function (Cai et al., 2010; Zhou et al., 2011) , possibly due to the compensatory actions of Taz, its endogenous activation by inhibition of different components of the Hippo pathway in the intestine results in increased proliferation and tumorigenesis. That is, although overexpression Yap experiments in vivo gave contradictory results (Barry and Camargo, 2013; Li and Clevers, 2010) , experiments modulating the endogenous levels of Yap strongly support its positive role in intestinal epithelial cell proliferation. Thus, deletion of both Mst1 and Mst2, whose role is to repress Yap function in the Hippo pathway, in the mouse intestine leads to crypt dysplasia in a Yap-dependent manner (Zhou et al., 2011) . Furthermore, intestine-specific deletion of Sav1 in mice, which correlates with Yap activation, also leads to crypt hyperplasia with highly proliferating cells, a phenotype that is rescued by the concomitant inactivation of Yap (Cai et al., 2010) . The link of Yap with intestinal cancer is apparent, since both double MST1/2 and Sav1 KO mice develop various forms of intestinal tumorigenesis (Cai et al., 2010; Zhou et al., 2011) . Moreover, Yap and Taz expression is increased in colorectal cancer (CRC) patients (Cai et al., 2010; Steinhardt et al., 2008; Wang et al., 2013; Zhou et al., 2011) , and it has been shown that Yap promotes resistance of CRC cells to chemotherapy (Touil et al., 2014) . Therefore, our data shown here, demonstrating that PKCz, in addition to interacting with and phosphorylating b-catenin at S45, also binds Yap and promotes its phosphorylation at S109/T110 to impair its stability, is of great relevance in ISC function.
The fact that PKCz impinges in both pathways is of particular interest given the existence of a previously described crosstalk between Yap and b-catenin. In this regard, several studies have reported the interaction of Yap with different components of the Wnt pathway, including Dvl, Axin1, and b-catenin itself (Azzolin et al., 2014; Rosenbluh et al., 2012) . The interaction with b-catenin is interesting because of the available data showing that Yap and b-catenin interact to promote cell survival and transformation of colon cancer cells (Rosenbluh et al., 2012) . Since PKCz destabilizes both b-catenin and Yap levels and inhibits their transcriptional activity even when overexpressed, a situation that mimics their activation state, this suggests that PKCz actions will be relevant not only during b-catenin regulation by the destruction complex but also once this is inhibited. More interestingly, we show here that PKCz immunoprecipitation pulls down not only b-catenin and Yap but also Axin1, indicating that PKCz is also part of the destruction complex. Interestingly, recently published data showed that Yap/Taz are essential for the recruitment of b-TrCP to the Axin1 complex and subsequent b-catenin inactivation in cells under conditions of inactive Wnt (Azzolin et al., 2014) . When cells are activated by Wnt, Yap/Taz are released from the complex and translocated to the nucleus (Azzolin et al., 2014) . Under these conditions, bTrCP cannot be recruited to the complex and b-catenin, although phosphorylated, cannot be polyubiquitinated and degraded, clogging the destruction complex, which allows newly synthesized b-catenin to be translocated to the nucleus (Azzolin et al., 2014) . Interestingly, cell stimulation with Wnt also promotes the degradation of Axin1 and therefore dislodges the destruction complex including the association with PKCz ( Figures 6D and 6E) . However, since PKCz directly binds b-catenin and Yap, this suggests that it regulates their stability probably when it is part of the destruction complex and also when released from Axin1, constituting an additional layer of control for b-catenin and Yap levels and functions.
In addition, our previously published data demonstrated that PKCz is part of a stress response triggered by nutrient deprivation, whereby PKCz's role is to restrain survival of CRC cells under these conditions (Ma et al., 2013) . In the present study, we show that PKCz deficiency prevents the inactivation of b-catenin and Yap by nutrient stress. This is in keeping with very recently reported evidence demonstrating that the Yap pathway is inhibited by energy stress through AMPK and the phosphorylation of AMOTL1 (DeRan et al., 2014) . These results, together with our data, indicate that Yap and b-catenin are exquisitely regulated during situations of nutrient deprivation to ensure that these pathways are not activated when stem cells do not have the necessary conditions to survive when activated. As PKCz is a tumor suppressor, our model suggests that its role is to block tumorigenesis by preventing metabolic reprogramming under conditions of nutrient deprivation and by inhibiting the activation of b-catenin and Yap to block the stem cell activation programs, specially under conditions of stress. 
IEC Isolation
Isolation of IECs was carried out as described previously (Egan et al., 2004) .
Statistical Analysis
Data are presented as the mean ± SEM. Significant differences between groups were determined with a Student's t test (two tailed). The significance level for statistical testing was set at p < 0.05. 
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